Company: TVRD
Filing Date: 2025-05-30
Form Type: S-1
Source: 0001104659-25-054853
Chunk: 330

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-05-30
Form: S-1
Chunk 330
---
 Institutes of Health, or NIH, related to methods and compositions for the use of STAT3 inhibitors in certain conditions like anaphylaxis, or the Licensed Patent Rights. Under the license for the Second BCM Agreement, the Company is permitted to make, have made, use, market, sell, offer to sell, lease and import products, processes or services that incorporate, utilize or are made with the use of the Licensed Patent Rights, or the BCM2 Licensed Products, in all fields of use.

StemMed assigned the BCM First Agreement and the BCM Second Agreement to the Company in connection with the transfer of all or substantially all of the assets and businesses to which the BCM License Agreements relate to in January and February 2018.

In accordance with BCM License Agreements, and in consideration for the rights and licenses granted to the Company, the Company agreed to pay BCM the following:

| a. | Annual maintenance fees, ranging from $30,000 to $50,000 per year, per license. |

| b. | Milestone payments, up to a low-seven digit figure in the aggregate. |

| c. | Royalty fees, set at low-single-digit of net sales of any BSM1 Licensed Products or BSM2 Licensed Products. |

Milestones include new drug filings, clinical trial stages, and New Drug Application approval by the FDA.

The Company recorded $ of annual maintenance fees during each of the years ended December 31, 2024 and 2023. The Company also incurred $ in milestone payments in each of the years ended December 31, 2024 and 2023 in relation to the initiation of Phase 2 clinical trials. To date, royalty fees have been incurred. All related license costs are expensed as incurred within research and development on the statements of operations.

16.Retirement Savings Plan The Company maintains a 401(k) Plan which is available to all employees. Under the terms of the 401(k) Plan, participants may elect to contribute up to 80% of their compensation or the statutory prescribed limits. The Company does not make any matching contributions to deferrals made by participants. 17.Segment Reporting The Company has onereportable segment relating to the discovery and development of novel orally bioavailable, small molecule therapies across a broad range of diseases driven by STAT3 with high unmet need. The Company’s CODM, its Chief Executive Officer and Chief Financial Officer, manages the Company’s operations on company-wide level for the purposes of allocating resources. The key measure of